4) One thought though — for my analysis, I placed the value of pipeline assets at ~ $ 250m (typical value for an oncology phIII product). (longtermvalue.wordpress.com)
Corcept Therapeutics (CORT)- Revenue growth is impressive on a quarterly and annual basis, its cash position is growing, and several pipeline assets (recorilant, CORT118335, CORT125281) could reach key inflection points in other areas such as oncology and NASH. (seekingalpha.com)
And with America's domestic energy boom still firing on all cylinders, there should be plenty of demand for high - quality midstream pipeline assets for years to come. (charlessizemore.com)